{
    "doi": "https://doi.org/10.1182/blood.V110.11.3291.3291",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=957",
    "start_url_page_num": 957,
    "is_scraped": "1",
    "article_title": "Role of Fas/FasL Pathway in Pediatric Idiopathic Neutropenia. ",
    "article_date": "November 16, 2007",
    "session_type": "Granulocytes, Monocytes and Macrophages",
    "topics": [
        "neutropenia",
        "tumor necrosis factor ligand superfamily member 6",
        "pediatrics",
        "antibodies",
        "immunoglobulin g",
        "interleukin-10",
        "interleukin-6",
        "aldesleukin",
        "annexins",
        "cancer"
    ],
    "author_names": [
        "Jae Won Joh",
        "Angel Callejas, B.S.",
        "Wendy Wong, M.D.",
        "Harvey Joel Cohen, M.D., Ph.D.",
        "Kari Nadeau, M.D., Ph.D.",
        "Michael Jeng, M.D."
    ],
    "author_affiliations": [
        [
            "Pediatrics, Lucile Packard Children\u2019s Hospital, Stanford, CA, USA"
        ],
        [
            "Pediatrics, Lucile Packard Children\u2019s Hospital, Stanford, CA, USA"
        ],
        [
            "Hematology/Oncology, Lucile Packard Children\u2019s Hospital, Stanford, CA, USA"
        ],
        [
            "Hematology/Oncology, Lucile Packard Children\u2019s Hospital, Stanford, CA, USA"
        ],
        [
            "Pediatrics, Lucile Packard Children\u2019s Hospital, Stanford, CA, USA"
        ],
        [
            "Hematology/Oncology, Lucile Packard Children\u2019s Hospital, Stanford, CA, USA"
        ]
    ],
    "first_author_latitude": "37.436041849999995",
    "first_author_longitude": "-122.17484145",
    "abstract_text": "Idiopathic neutropenia in children is marked by low neutrophil counts (<1500/ul) circulating in the peripheral blood in patients whose disease spontaneously develops unrelated to drugs, cancers, specific antibodies, or known genetic deficiencies. Neutrophils, PBMCs and plasma were purified/obtained from 24 subjects (n=17 acute and n=7 chronic) with idiopathic neutropenia, aged 3 months to 11 yrs. After screening a number of cytokines (IL-2, IL-4 IL-6, IL-8, IL-10, IFN-\u03b3, TNF-\u03b1), growth factors (GCSF), cell death factors (Fas, FasL, Granzymes/Perforin), and chemokines (CCL5, XCL1, XCR1), QT-PCR studies of neutropenic subjects\u2019 neutrophils indicated an up-to-14-fold increase in Fas transcripts compared to age-matched healthy control neutrophils. FACS analysis on patient neutrophils demonstrated increased expression of Fas (93%+/\u2212 15%) compared to healthy control neutrophils (41%+/\u221211%). No increase in Fas surface expression was seen on PBMCs or on CD4+T cells from neutropenia patients compared to healthy controls. Studies of patient plasma showed increased FasL in acute and chronic patients (up to 40-fold higher). Increased IL-6 and IL-10 levels in plasma were another distinctive characteristic of neutropenic patients. Healthy control neutrophils incubated in neutropenic patient plasma for 4 hrs showed greater rates of apoptosis (evaluated by PI/Annexin; up to 38-fold higher) compared to incubation with healthy control plasma. Heat denaturation, IgG exclusion, and size separation studies suggest that the killing factor(s) is a heat-sensitive protein which is not IgG and has a MW between 35 and 100 kD. Blocking with anti-FasL antibodies incubated with patient plasma caused a statistically significant 5-fold to 11-fold decrease in neutrophil apoptosis, approaching the rates of healthy controls, implicating FasL as a major mediator of neutrophil regulation. Thus, the Fas/FasL pathway may play an important role in idiopathic neutropenia.  Patient number . Chronicity . Age . FasL (pg/ml) . Anti-neutrophil Ab . Fold increase in neutrophil death over control plasma . Fold increase in apoptosis over control plasma . 1 chronic 2 yrs 7\u00b11 positive 6.5\u00b10.7 8.5\u00b10.8 2 chronic 18 mo. 6\u00b11 positive 7.3\u00b10.5 8.1\u00b10.2 3 chronic 23 mo. 5\u00b10.5 wk positive/neg 7.8\u00b10.6 8.5\u00b10.4 4 chronic 1 yr 5\u00b12 positive 6.5\u00b10.5 7.3\u00b10.6 5 chronic 5 yrs 7\u00b11 wk positive 6.1\u00b10.9 2.7\u00b10.2 6 chronic 20 mo. 10\u00b11 negative 11.3\u00b11.4 2.1\u00b10.5 7 chronic 11 mo. 6\u00b11 negative 6.1\u00b10.8 5.7\u00b10.6 8 acute 2 yrs 16\u00b12 N/A 18.7\u00b11.3 22.4\u00b12.9 9 acute 2 yrs 18\u00b13 negative 12.0\u00b12.1 19.1\u00b12.5 10 acute 5 yrs 4\u00b11 negative 2.5\u00b10.5 2.6\u00b10.4 11 acute 11 mo. 3\u00b10.6 N/A 1.5\u00b10.3 2.1\u00b10.2 12 acute 3 yrs 17\u00b11 negative 15.3\u00b11.2 19.2\u00b10.8 13 acute 2 yrs 40\u00b13 negative 22.9\u00b11.4 38.4\u00b12.4 14 acute 2 yrs 21\u00b12 N/A 14.3\u00b11.0 20.5\u00b11.2 15 acute 8 mo. 10\u00b10.9 N/A 9.6\u00b10.8 12.0\u00b11.6 16 acute 17 mo. 19\u00b13 negative 21.3\u00b12.2 26.7\u00b13.5 17 acute 6 yrs 8\u00b11 N/A 6.7\u00b11.3 11.5\u00b12.1 18 acute 3 yrs 9\u00b12 N/A 7.2\u00b12.6 8.8\u00b11.5 19 acute 11 yrs 12\u00b12 negative 14.8\u00b10.9 17.4\u00b11.9 20 acute 5 yrs 6\u00b11 negative 3.4\u00b10.6 5.2\u00b10.7 21 acute 4 mo. 8\u00b12 N/A 6.2\u00b11.0 8.1\u00b12.2 22 acute 3 mo. 27\u00b13 N/A 21.4\u00b13.5 39.4\u00b12.4 23 acute 11 yrs 22\u00b11 negative 17.2\u00b13.0 24.3\u00b12.8 24 acute 2 yrs 18\u00b12 positive 15.8\u00b11.2 25.0\u00b11.7 Representative control N/A 4 yrs 1.3\u00b10.4 N/A 1.2\u00b10.3 0.8\u00b10.4 Patient number . Chronicity . Age . FasL (pg/ml) . Anti-neutrophil Ab . Fold increase in neutrophil death over control plasma . Fold increase in apoptosis over control plasma . 1 chronic 2 yrs 7\u00b11 positive 6.5\u00b10.7 8.5\u00b10.8 2 chronic 18 mo. 6\u00b11 positive 7.3\u00b10.5 8.1\u00b10.2 3 chronic 23 mo. 5\u00b10.5 wk positive/neg 7.8\u00b10.6 8.5\u00b10.4 4 chronic 1 yr 5\u00b12 positive 6.5\u00b10.5 7.3\u00b10.6 5 chronic 5 yrs 7\u00b11 wk positive 6.1\u00b10.9 2.7\u00b10.2 6 chronic 20 mo. 10\u00b11 negative 11.3\u00b11.4 2.1\u00b10.5 7 chronic 11 mo. 6\u00b11 negative 6.1\u00b10.8 5.7\u00b10.6 8 acute 2 yrs 16\u00b12 N/A 18.7\u00b11.3 22.4\u00b12.9 9 acute 2 yrs 18\u00b13 negative 12.0\u00b12.1 19.1\u00b12.5 10 acute 5 yrs 4\u00b11 negative 2.5\u00b10.5 2.6\u00b10.4 11 acute 11 mo. 3\u00b10.6 N/A 1.5\u00b10.3 2.1\u00b10.2 12 acute 3 yrs 17\u00b11 negative 15.3\u00b11.2 19.2\u00b10.8 13 acute 2 yrs 40\u00b13 negative 22.9\u00b11.4 38.4\u00b12.4 14 acute 2 yrs 21\u00b12 N/A 14.3\u00b11.0 20.5\u00b11.2 15 acute 8 mo. 10\u00b10.9 N/A 9.6\u00b10.8 12.0\u00b11.6 16 acute 17 mo. 19\u00b13 negative 21.3\u00b12.2 26.7\u00b13.5 17 acute 6 yrs 8\u00b11 N/A 6.7\u00b11.3 11.5\u00b12.1 18 acute 3 yrs 9\u00b12 N/A 7.2\u00b12.6 8.8\u00b11.5 19 acute 11 yrs 12\u00b12 negative 14.8\u00b10.9 17.4\u00b11.9 20 acute 5 yrs 6\u00b11 negative 3.4\u00b10.6 5.2\u00b10.7 21 acute 4 mo. 8\u00b12 N/A 6.2\u00b11.0 8.1\u00b12.2 22 acute 3 mo. 27\u00b13 N/A 21.4\u00b13.5 39.4\u00b12.4 23 acute 11 yrs 22\u00b11 negative 17.2\u00b13.0 24.3\u00b12.8 24 acute 2 yrs 18\u00b12 positive 15.8\u00b11.2 25.0\u00b11.7 Representative control N/A 4 yrs 1.3\u00b10.4 N/A 1.2\u00b10.3 0.8\u00b10.4 View Large"
}